Lunar revenues climb, but profit falls
Bone densitometry firm Lunar’s effort to grow revenues by targeting the physician office market is experiencing success. The Madison, WI, company enjoyed a 22% rise in revenues for its third quarter (end-September). Lower profit margins associated
Bone densitometry firm Lunars effort to grow revenues by targeting the physician office market is experiencing success. The Madison, WI, company enjoyed a 22% rise in revenues for its third quarter (end-September). Lower profit margins associated with the initiative resulted in declining net income for the firm, however.
For the quarter, Lunar recorded revenues of $22.8 million, compared with $18.7 million in the third quarter of 1997. Lunars net income for the third quarter of 1998 was $1.2 million, compared with $2 million in the third quarter of 1997. Lunars profit for the most recent quarter was also affected by a $580,000 charge for the settlement of patent litigation.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
